Background
==========

Breast cancer has great genetic heterogeneity, most probably influenced by the contribution of combined variations in steroid hormones, metabolism, cell growth/apoptosis, and DNA repair genes. Genetic variations in DNA repair may impact repair functions, DNA damage, and breast cancer risk \[[@b1-amjcaserep-13-218]\]. Available evidence indicates that the majority of cancers show instability in specific sequence motifs of dinucleotide repeats. This phenotype of microsatellite instability (MSI) is commonly observed in DNA mismatch repair (MMR) pathway defects \[[@b2-amjcaserep-13-218]\]. A decreased activity of MMR confers a mutator phenotype, by which the rate of spontaneous mutation is greatly elevated \[[@b3-amjcaserep-13-218]\]. In addition, DNA repair mechanisms greatly affect the response to cytotoxic treatments, including radiation and chemotherapy, that target cellular DNA \[[@b4-amjcaserep-13-218]\].

Case Report
===========

A 19-year-old woman presented to the outpatient clinic of the National Cancer Institute (NCI), Cairo University, with a painless right breast mass of 5 months duration, which had progressively increased in size. Three months following appearance of the breast mass, the patient complained of pain related to the left knee, then appearance of a mass in the left knee. The patient denied any personal or family history of malignancy. Upon examination, there was a huge mass (10×12 cm), involving almost the whole of the right breast and invading the overlying skin, causing nipple ulceration. The mass was associated with bilateral axillary lymph nodes enlargement, hard and amalgamated on the ipsilateral side, while mobile and firm on the contralateral one ([Figure 1](#f1-amjcaserep-13-218){ref-type="fig"}). The clinical and radiological characteristics of the breast mass were highly suspicious of malignancy. Biopsy from the mass revealed invasive duct carcinoma grade II with scattered lympho-vascular permeation ([Figure 2A,B](#f2-amjcaserep-13-218){ref-type="fig"}). Immunostaining for estrogen and progesterone receptors were positive (ER+, PR +), and Her-2/neu was overexpressed (score 3). Fine-needle aspiration cytology (FNAC) revealed metastatic deposits in the ipsilateral and the contralateral axillary nodes.

Plain X-ray of the chest and liver ultrasonography were free of metastatic deposits, while bone scan showed a single area of increased uptake in the supracondylar region of the left femur, but the rest of the skeleton was free. Local X-ray of the left femur showed an irregular, dense, ill-defined, osteosclerotic lesion, with possible soft tissue extension ([Figure 3](#f3-amjcaserep-13-218){ref-type="fig"}), which was confirmed by MRI. Radiological features of the lesion raised the suspicion of second primary malignant lesion rather than breast cancer, so biopsy from the bone lesion was taken. Pathological examination showed a malignant neoplasm formed of proliferating pleomorphic large cells having scanty cytoplasm, and hyperchromatic nuclei with related deposition of thin lace-like branching osteoid matrix and negative immunostaining for CK ([Figure 2C,D](#f2-amjcaserep-13-218){ref-type="fig"}), excluding breast origin and confirming the diagnosis of conventional osteosarcoma GII, osteoblastic type. Hence, the final diagnosis was a case with double primary tumors: a) invasive duct carcinoma of the right breast, metastatic to contra-lateral axillary LNs (T4b N2a M1), and b) osteosarcoma of the LT femur (Enneking stage IIB). Chemotherapy treatment was started with 1 cycle of FEC 100 regimen (cyclophosphamide, epirubicin & 5-fluorouracil), which was associated with regression of the breast mass, but progression of the osteosarcoma. The patient was then shifted to another regimen, which has activity in both types of tumors (docetaxel 70 mg/m^2^ D1, Cisplatin 70 mg/m^2^ D1 & Epirubicin 80 mg/m^2^ D1), and she showed a good partial clinical response in both lesions.

Ten micron thick sections were obtained from paraffin blocks of both biopsies (breast invasive duct carcinoma & Lt femur osteosarcoma) and were subjected to genetic testing to search for mismatch repair (MMR) genes aberrations as a highly possible explanation for the multiple, early-onset neoplasms in the patient. DNA and RNA extraction was done using commercially available DNA& RNA extraction kits (Qiagen) according to manufacturer's protocols. Extracted DNA was used to detect: a) promoter hypermethylation (PM) in *BRCA1, BRCA2, MLH1, MSH2 and GPB6* \[[@b5-amjcaserep-13-218]\], b) mutations and microsatellite instability (MSI) of *MLH1* and *MSH2* \[[@b6-amjcaserep-13-218]\]*,* c) mutations in exons 5--9 of the *p53* and exons 6, 7, 11 of *BRCA-1* genes by polymerase chain reaction (PCR)/sequencing \[[@b7-amjcaserep-13-218],[@b8-amjcaserep-13-218]\], d) loss of heterozygosity (LOH) in exons 6, 7,11 of *BRCA-1* \[[@b8-amjcaserep-13-218]\], and e) mutations of *K12/13-ras* by PCR/RFLP \[[@b9-amjcaserep-13-218]\]. The RNA was used to detect *BRCA1*&*2, ERCC1, RRM1*, *MSH2, MLH1 and MSH6* expression by quantitative real time PCR \[[@b5-amjcaserep-13-218],[@b10-amjcaserep-13-218],[@b11-amjcaserep-13-218]\]. *Her2/neu* gene amplification in breast and osteosarcoma was determined by chromogen *in situ* hybridization (CISH) with Invitrogen, Spot Light *HER2* detection kit according to manufacturer's instructions.

*Her2/neu* gene amplification was detected in the breast tumor (BT) but not in the osteosarcoma (OS). *P53* mutations were detected in BT and OS, though at different codons ([Figure 4](#f4-amjcaserep-13-218){ref-type="fig"}), while *K13-ras* mutations was detected in OS only ([Figure 5](#f5-amjcaserep-13-218){ref-type="fig"}). *BRCA1* gene mutations were concentrated at exons 11 and 1, whereas LOH concentrated at exons 11 followed by 6 ([Tables 1](#t1-amjcaserep-13-218){ref-type="table"}, [2](#t2-amjcaserep-13-218){ref-type="table"}). No mutations were detected in *BRCA2* gene, though reduced mRNA expression of *BRCA1*&*2* ([Figure 6](#f6-amjcaserep-13-218){ref-type="fig"}) was evident in both tumor samples. Similarly, *ERCC1, MLH1, MSH2* mRNA expression was reduced in both tumors, especially in the OS, whereas *MSH6* was normally expressed and *RRM1* was overexpressed in both tumors. *MLH1* and *MSH2* showed PM in both tumors ([Figure 7](#f7-amjcaserep-13-218){ref-type="fig"}), MSI in BT, and different mutational events in both tumors ([Tables 1](#t1-amjcaserep-13-218){ref-type="table"}, [2](#t2-amjcaserep-13-218){ref-type="table"} & [Figure 8](#f8-amjcaserep-13-218){ref-type="fig"}).

Discussion
==========

In the present case, a 19-year-old woman attended the NCI clinics, with breast and femoral bone lesions that proved to be invasive duct carcinoma (IDC) and osteosarcoma (OS); respectively. A genetic predisposition was highly suspected, though the patient did not fit into any of the well-known genetic syndromes such as Li-Fraumeni (LF), ataxia telangiectasia (AT) or Lynch syndrome (LS). Although in LS various organs and organ systems may be affected by malignancies in addition to colorectal and endometrial cancer \[[@b12-amjcaserep-13-218],[@b13-amjcaserep-13-218]\], it usually affects individuals in the 4^th^ or 5^th^ decade; but occasionally patients may be younger (in the 3^rd^ decade) or older (in the 6^th^ or 7^th^ decade) \[[@b14-amjcaserep-13-218]\]. However, LS is characterized by a germline heterozygous defect or mutations in one of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6) transmitted in an autosomal-dominant manner. In our case, the young age at presentation and the negative family history led us to exclude LS, but the early onset and the multiplicity of the lesions raised a high possibility of MMR gene defects. Therefore, we sought to assess for MMR genes aberrations as a possible cause for this case with multiple, early onset malignancies.

MMR gene defects have been previously reported in solid tumors, including sporadic and familial breast cancer and OS \[[@b15-amjcaserep-13-218],[@b16-amjcaserep-13-218]\]. Our patient showed reduced mRNA of the assessed MMR genes in both tumor samples; mainly MLH1, MSH2 and MSH6. However, there was a difference between both lesions, since OS showed marked reduction of MLH1, MSH2 compared to BT, whereas MSH6 was much reduced in the BT sample. This reduction in the expression of MLH1, MSH2 and MSH6 could be induced by aberrant PM, MSI, mutations or more than one defect.

Our mutational analysis showed a difference in the mutation pattern in both lesions, but several mutational events were detected in both lesions. In general, the OS revealed a slightly higher mutation frequency (MF) than the BT, especially for MSH2 and p53 genes, suggesting that the OS might have developed later than the BT as a consequence of accumulating genetic damage due to ineffective MMR, although the patient presented with both lesions. On the other hand, BRCA1 showed more mutations in the BT. The mutations reported here have been previously reported in other solid and hematological tumors \[[@b17-amjcaserep-13-218],[@b18-amjcaserep-13-218]\].

Recently, other DNA repair genes have been identified that can contribute to tumor development and progression. Among these are the ERCC1 (excision repair cross-complementing 1) and BRCA1, which are key genes in NER, double-strand break repair, and mismatch repair, as well as the ribonucleotide reductase M1 (RRM1), which is involved in DNA synthesis, catalyzing the biosynthesis of DNA from the corresponding ribonucleotides, and involved in gemcitabine resistance \[[@b10-amjcaserep-13-218]\]. Using real-time quantitative PCR, we found that BRCA1&2, and ERCC1 were markedly reduced in BT and OS, but again to a higher extent in OS, whereas RRM1 was overexpressed in both tumors. BRCA1 gene aberrations could be attributed to mutations, microsatellite instability, and/or loss of heterozygosity (LOH), which is in accordance with previous reports in the literature, whereas reduced BRCA2 and increased RRM1 expression are probably induced by post-translation modification \[[@b6-amjcaserep-13-218],[@b10-amjcaserep-13-218],[@b18-amjcaserep-13-218],[@b19-amjcaserep-13-218]\].

As a consequence of the multiple defects in the key MMR genes reported in our case, other genetic errors were expected. Therefore, we assessed both tumors (BT&OS) for mutations in some other genes that are frequently mutated in solid tumors and we were able to detect several mutational events in K12/13-ras and p53 genes in BT and OS, although at different sites ([Tables 1](#t1-amjcaserep-13-218){ref-type="table"}, [2](#t2-amjcaserep-13-218){ref-type="table"}). This confirmed our assumption that other genetic errors could be present as a consequence of MMR genes defects, although not detected here, and this could have led to the development of other malignancies if the patients survived longer.

Conclusions
===========

We conclude that MMR gene defects through mutations, PM, MSI or other mechanisms could explain simultaneous or consequent development of multiple solid tumors, especially in a young patient. These tumors might not reveal (exploit) the full picture of certain hereditary cancer syndromes, but it might confer genetic predisposition. With time, there is increased probability to acquire more genetic damage, and consequently, there is a high possibility of developing more tumors and/or increasing aggression and resistance of the existing tumors to the current treatment modalities. Therefore, it is important for clinicians and geneticists to suspect MMR gene defects and to recommend techniques for detection of these defects, especially when dealing with multiple tumors in a young patient, and particularly in patients who have small families or hypomorphic mutations (mutations leading to an abnormal protein, even with residual function). It is also important to recommend close follow-up for those patients and genetic counseling for their family members to detect genetic abnormalities in MMR genes and other genes, which are linked to the familial cancer syndromes, as well as for early detection of any malignancy that might develop.

![The breast mass involving almost the whole breast with ulcerated nipple.](amjcaserep-13-218-g001){#f1-amjcaserep-13-218}

![(**A**) The tumor area from the breast mass showing invasive groups of malignant moderately differentiated ductal cells (x), (**B**) the same tumor area showing positive immunostaining of the malignant ductal cells for Her 2 neu (+3) (×200), (**C**) a microscopic picture of the bony lesion showing malignant spindle cells associated with deposition of osteoid, which supports the diagnosis of osteosarcoma, and (**D**) negative immunostaining for cytokeratin CK in the malignant osteoblasts.](amjcaserep-13-218-g002){#f2-amjcaserep-13-218}

![X-ray of the left femur showing an ill defined irregular osteoscelorotic lesion in the supracondylar region with soft tissue extension.](amjcaserep-13-218-g003){#f3-amjcaserep-13-218}

![Sequence analysis of the p53 gene for the two lesions showing mutation in the p53 gene (GCC to ACC) in the osteosarcoma (OS) but not in breast invasive duct carcinoma (IDC).](amjcaserep-13-218-g004){#f4-amjcaserep-13-218}

![An ethedium bromide-stained gel showing the wild type of codon 12-ras (125bp band) both in OS and IDC. Mutation in codon 13-ras was detected in OS (157bp band) only whereas the IDC showed no mutations.](amjcaserep-13-218-g005){#f5-amjcaserep-13-218}

![An ethedium bromide-stained gel for the RT-PCR showing reduction/loss of BRCA1, BRCA2, MLH1, MSH2 mRNA in the IDC as well as in the OS samples. BRCA2 showed reduced expression in OS only while MSH6 was normally expressed.](amjcaserep-13-218-g006){#f6-amjcaserep-13-218}

![Methylation specific PCR showing promoter hypermethylation (PM) of MLH1 and MSH2 genes both in the IDC and OS samples.](amjcaserep-13-218-g007){#f7-amjcaserep-13-218}

![Microsatellite instability (MSI) from the IDC and the OS showing MSI in the MLH1 and MSH2 gene *loci* in the IDC but not in OS.](amjcaserep-13-218-g008){#f8-amjcaserep-13-218}

###### 

Summary of mutational analysis of the studied genes in breast tumor.

  **Gene**   **Exon**       **Codon**               **Nucleotide change**   **Mutation status**
  ---------- -------------- ----------------------- ----------------------- -------------------------------------
  hMSH2      8              453                     A1358\-\-\-\-\-\--T     Splice site\-\-\-\-\--30bp deletion
  12         SD of exon12   Del of 11bp at 2005     Splice defect           
  15         878            2633 del (AG)           Frameshift              
                                                                            
  MLH1       12             397                     1190 del (T)            Frameshift
                                                                            
  BRCA1      11             64                      TGT-GGT                 Missense
             392            1294--1333 del          Frameshift              
             1252           3875--3878 del          Frameshift              
             1656           5085--5103 del          Frameshift              
             1773           ACCC-ACCCC (ins)        Frameshift              
                                                                            
  P53        4              72                      GGC-CCC                 Missense
  5          138            GCC-ACC                 Missense                
  5          163            TAC-AAC                 Missense                
  5          161            1 base pair insertion   Frameshift              
  6          209            AGA-ACA                 Frameshift              
  7          245            GGC-AGC                 Missense                
  8          280            AGA-ACA                 Frameshift              

###### 

Summary of mutational analysis of the studied genes in osteosarcoma.

  **Gene**   **Exon**   **Codon**             **Nucleotide change**                 **Mutation status**
  ---------- ---------- --------------------- ------------------------------------- ---------------------
  hMSH2      1          45                    134 del of 29bp                       frameshift
  8          453        A1358\-\-\-\-\-\--T   Splice site\-\-\-\-\--30bp deletion   
  15         878        2633 del (AG)         Frameshift                            
  7          389        C1165\-\-\-\--T       Arg\-\-\-\-\--Stop codon              
                                                                                    
  MLH1       12         397                   1190 del (T)                          Frameshift
                                                                                    
  BRCA1      11         64                    TGT-GGT                               Missense
             392        1294--1333 del        Frameshift                            
             1443       CGA-GGA               Missense                              
             1773       ACCC-ACCCC (ins)      Frameshift                            
                                                                                    
  P53        4          72                    GGC-CCC                               Missense
  5          126        TAC-TAG               STOP CODON                            
  5          175        CGC-CAC               Missense                              
  5          163        TAC-AAC               Missense                              
  5          161        1bp insertion         Frameshift                            
  6          205        TAT-CAT               Missense                              
  7          241        TCC-TTC               Missense                              
  7          245        GGC-AGC               Missense                              
  8                     3′+GT-GG              Frameshift                            

[^1]: **Full-text PDF:** <http://www.amjcaserep.com/fulltxt.php?ICID=883382>
